Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-268019-b booster versus Comirnaty booster in adults previously vaccinated with Comirnaty
jRCT2031210470Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing S-268019-b booster with Comirnaty booster (2 arms). Primary endpoints: SARS-CoV-2 neutralizing antibody titer on Day 29, Geometric mean titer ratio on Day 29 and 1 more. Started Dec 2021; status: completed.
02
Drugs
S-268019-btozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210470.